Autopsy report · NCT01641939
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 8 months before it stopped.
- 415 participants enrolled.
- Results were posted on the registry 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Conditions
- Gastric Cancer
- Interventions
- Taxane; trastuzumab emtansine; trastuzumab emtansine
- Participants
- 415
- Sites
- 148
- Countries
- Argentina, Belgium, Brazil, Canada, China, Czechia, Finland, France, Germany, Guatemala, Hungary, Italy and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.